Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
5 Results for "
Marginal zone lymphoma
" in MedChemExpress (MCE) Product Catalog:
Products (5)
5 Results for "Marginal zone lymphoma" in MCE Product Catalog:
Target:
Research Areas:
Mal-Phe-C4-VC-PAB-MMAE is a drug-linker conjugate for ADC composed of MMAE conjugated to the Mal-Phe-C4-VC-PAB linker. Mal-Phe-C4-VC-PAB-MMAE can be used to synthesize antibody-drug conjugates targeting ROR1, and the resulting ADC exhibits in vitro tumor cell proliferation inhibitory activity. Mal-Phe-C4-VC-PAB-MMAE is applicable to research on cancers expressing ROR1 .
Cat. No.: HY-151395
CAS No.: 3051788-87-2
Target:
Research Areas:
Tubulin polymerization-IN-34 is an inhibitor of [1,2]oxazoloisoindoles tubulin polymerization, demonstrates high selectivity against marginal zone lymphoma VL51 cell line .
Cat. No.: HY-151396
CAS No.: 3051788-88-3
Target:
Research Areas:
Tubulin polymerization-IN-35 is an inhibitor of [1,2]oxazoloisoindoles tubulin polymerization, demonstrates high selectivity against marginal zone lymphoma VL51 cell line .
Cat. No.: HY-151394
CAS No.: 3051788-72-5
Target:
Research Areas:
Tubulin polymerization-IN-33 is an inhibitor of [1,2]oxazoloisoindoles tubulin polymerization, exhibits high antiproliferative activity against the NCI panel .
Cat. No.: HY-P991514A
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
